ZA200604495B - Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride - Google Patents

Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride Download PDF

Info

Publication number: ZA200604495B
Authority: ZA; South Africa
Prior art keywords: azithromycin; multiparticulates; carrier; mixture; molten
Prior art date: 2003-12-04

Application number

ZA200604495A

Other languages

English (en)

Inventor

Appel Leah Elizabeth

Crew Marshall David

Friesen Dwayne Thomas

Herbig Scott Max

Lemott Steven Ross

Lo Julian Belknap

Lyon David Keith

Mccray Scott Baldwin

Newbold David Dixon

Ray Roderick Jack

West James Blair

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-04

Filing date

2006-06-01

Publication date

2008-03-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34652484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200604495(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-06-01 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2008-03-26 Publication of ZA200604495B publication Critical patent/ZA200604495B/en

Links

MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims description 408
229960004099 azithromycin Drugs 0.000 title claims description 341
239000000203 mixture Substances 0.000 title claims description 231
238000000034 method Methods 0.000 title claims description 112
230000008569 process Effects 0.000 title claims description 61
229920001983 poloxamer Polymers 0.000 title claims description 21
125000005456 glyceride group Chemical group 0.000 title claims description 10
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 title description 14
229960000502 poloxamer Drugs 0.000 title description 7
VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 claims description 59
229960004924 azithromycin dihydrate Drugs 0.000 claims description 59
230000015572 biosynthetic process Effects 0.000 claims description 55
239000000725 suspension Substances 0.000 claims description 43
239000001993 wax Substances 0.000 claims description 33
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 30
-1 polyoxyethylene Polymers 0.000 claims description 30
238000004090 dissolution Methods 0.000 claims description 25
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 23
239000004200 microcrystalline wax Substances 0.000 claims description 22
235000019808 microcrystalline wax Nutrition 0.000 claims description 22
238000002844 melting Methods 0.000 claims description 18
230000008018 melting Effects 0.000 claims description 18
239000003623 enhancer Substances 0.000 claims description 17
238000012545 processing Methods 0.000 claims description 15
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 14
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 13
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 12
229920001223 polyethylene glycol Polymers 0.000 claims description 12
235000002639 sodium chloride Nutrition 0.000 claims description 11
239000002202 Polyethylene glycol Substances 0.000 claims description 10
229940075507 glyceryl monostearate Drugs 0.000 claims description 10
239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 10
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 10
239000003937 drug carrier Substances 0.000 claims description 9
235000013871 bee wax Nutrition 0.000 claims description 8
239000012166 beeswax Substances 0.000 claims description 8
239000012188 paraffin wax Substances 0.000 claims description 8
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 8
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 7
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
229960000541 cetyl alcohol Drugs 0.000 claims description 6
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 claims description 6
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
229930006000 Sucrose Natural products 0.000 claims description 5
239000005720 sucrose Substances 0.000 claims description 5
239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 4
RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 3
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
235000004279 alanine Nutrition 0.000 claims description 3
125000005907 alkyl ester group Chemical group 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
239000001110 calcium chloride Substances 0.000 claims description 3
229910001628 calcium chloride Inorganic materials 0.000 claims description 3
235000011148 calcium chloride Nutrition 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 3
229940046813 glyceryl palmitostearate Drugs 0.000 claims description 3
229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
235000011147 magnesium chloride Nutrition 0.000 claims description 3
229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
235000019341 magnesium sulphate Nutrition 0.000 claims description 3
239000000845 maltitol Substances 0.000 claims description 3
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 3
235000010449 maltitol Nutrition 0.000 claims description 3
229940035436 maltitol Drugs 0.000 claims description 3
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
239000008389 polyethoxylated castor oil Substances 0.000 claims description 3
229920000136 polysorbate Polymers 0.000 claims description 3
229940068965 polysorbates Drugs 0.000 claims description 3
229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
235000011009 potassium phosphates Nutrition 0.000 claims description 3
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
235000011151 potassium sulphates Nutrition 0.000 claims description 3
229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
235000017550 sodium carbonate Nutrition 0.000 claims description 3
239000011780 sodium chloride Substances 0.000 claims description 3
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
235000011152 sodium sulphate Nutrition 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
235000010356 sorbitol Nutrition 0.000 claims description 3
239000000811 xylitol Substances 0.000 claims description 3
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
235000010447 xylitol Nutrition 0.000 claims description 3
229960002675 xylitol Drugs 0.000 claims description 3
150000005215 alkyl ethers Chemical class 0.000 claims description 2
239000001103 potassium chloride Substances 0.000 claims description 2
235000011164 potassium chloride Nutrition 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 description 138
239000002253 acid Substances 0.000 description 66
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
125000004185 ester group Chemical group 0.000 description 56
239000002245 particle Substances 0.000 description 54
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
229940079593 drug Drugs 0.000 description 38
239000003814 drug Substances 0.000 description 38
239000012530 fluid Substances 0.000 description 34
239000000523 sample Substances 0.000 description 34
239000000969 carrier Substances 0.000 description 32
150000002148 esters Chemical class 0.000 description 31
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 28
239000002552 dosage form Substances 0.000 description 26
150000004683 dihydrates Chemical class 0.000 description 25
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
239000013078 crystal Substances 0.000 description 23
239000000463 material Substances 0.000 description 23
238000002156 mixing Methods 0.000 description 22
238000012216 screening Methods 0.000 description 22
238000007127 saponification reaction Methods 0.000 description 21
238000006467 substitution reaction Methods 0.000 description 21
239000007787 solid Substances 0.000 description 20
239000012453 solvate Substances 0.000 description 19
238000013270 controlled release Methods 0.000 description 18
229920001992 poloxamer 407 Polymers 0.000 description 18
DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 17
230000000694 effects Effects 0.000 description 17
239000000155 melt Substances 0.000 description 17
239000000872 buffer Substances 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
238000007922 dissolution test Methods 0.000 description 14
238000012360 testing method Methods 0.000 description 14
238000004458 analytical method Methods 0.000 description 13
238000000889 atomisation Methods 0.000 description 13
238000000634 powder X-ray diffraction Methods 0.000 description 13
239000002904 solvent Substances 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
230000009257 reactivity Effects 0.000 description 12
239000003795 chemical substances by application Substances 0.000 description 11
239000007788 liquid Substances 0.000 description 11
239000000126 substance Substances 0.000 description 11
HQUPLSLYZHKKQT-WVVFQGGUSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-o Chemical compound O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HQUPLSLYZHKKQT-WVVFQGGUSA-N 0.000 description 10
229960003256 azithromycin monohydrate Drugs 0.000 description 10
239000000843 powder Substances 0.000 description 10
239000012080 ambient air Substances 0.000 description 9
230000008901 benefit Effects 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
238000009472 formulation Methods 0.000 description 8
239000007789 gas Substances 0.000 description 8
230000014509 gene expression Effects 0.000 description 8
238000010438 heat treatment Methods 0.000 description 8
235000019271 petrolatum Nutrition 0.000 description 8
150000003839 salts Chemical class 0.000 description 8
125000001424 substituent group Chemical group 0.000 description 8
230000003113 alkalizing effect Effects 0.000 description 7
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
239000006104 solid solution Substances 0.000 description 7
229910001220 stainless steel Inorganic materials 0.000 description 7
239000010935 stainless steel Substances 0.000 description 7
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
235000021355 Stearic acid Nutrition 0.000 description 6
239000011521 glass Substances 0.000 description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
239000012535 impurity Substances 0.000 description 6
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000012085 test solution Substances 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
239000003643 water by type Substances 0.000 description 6
150000001298 alcohols Chemical class 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
238000001816 cooling Methods 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
230000002496 gastric effect Effects 0.000 description 5
238000000227 grinding Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 5
239000000347 magnesium hydroxide Substances 0.000 description 5
229910001862 magnesium hydroxide Inorganic materials 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
235000019809 paraffin wax Nutrition 0.000 description 5
239000012071 phase Substances 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
239000008117 stearic acid Substances 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
229940001496 tribasic sodium phosphate Drugs 0.000 description 5
229920002023 Pluronic® F 87 Polymers 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
239000004809 Teflon Substances 0.000 description 4
229920006362 Teflon® Polymers 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
239000003570 air Substances 0.000 description 4
239000012298 atmosphere Substances 0.000 description 4
239000002178 crystalline material Substances 0.000 description 4
239000007857 degradation product Substances 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
150000004682 monohydrates Chemical class 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004320 controlled atmosphere Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000009826 distribution Methods 0.000 description 3
230000032050 esterification Effects 0.000 description 3
238000005886 esterification reaction Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000001125 extrusion Methods 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000003801 milling Methods 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
235000021317 phosphate Nutrition 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
125000006850 spacer group Chemical group 0.000 description 3
238000009987 spinning Methods 0.000 description 3
230000003068 static effect Effects 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000005809 transesterification reaction Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical class CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
239000005695 Ammonium acetate Substances 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
241000167854 Bourreria succulenta Species 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
241000234295 Musa Species 0.000 description 2
235000018290 Musa x paradisiaca Nutrition 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
229940043376 ammonium acetate Drugs 0.000 description 2
235000019257 ammonium acetate Nutrition 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
229940075614 colloidal silicon dioxide Drugs 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000000112 cooling gas Substances 0.000 description 2
239000000110 cooling liquid Substances 0.000 description 2
239000003431 cross linking reagent Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
229940111685 dibasic potassium phosphate Drugs 0.000 description 2
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 2
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
230000009977 dual effect Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
229960001031 glucose Drugs 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
239000003120 macrolide antibiotic agent Substances 0.000 description 2
239000000395 magnesium oxide Substances 0.000 description 2
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
239000000391 magnesium silicate Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
229960003893 phenacetin Drugs 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000006069 physical mixture Substances 0.000 description 2
229940044476 poloxamer 407 Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
239000008213 purified water Substances 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
238000007711 solidification Methods 0.000 description 2
230000008023 solidification Effects 0.000 description 2
229960002920 sorbitol Drugs 0.000 description 2
241000894007 species Species 0.000 description 2
238000005507 spraying Methods 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
229940062627 tribasic potassium phosphate Drugs 0.000 description 2
PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
229910000406 trisodium phosphate Inorganic materials 0.000 description 2
235000019801 trisodium phosphate Nutrition 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical class CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
101100231514 Caenorhabditis elegans ceh-12 gene Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001553014 Myrsine salicina Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
229920002511 Poloxamer 237 Polymers 0.000 description 1
229920002517 Poloxamer 338 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000000149 argon plasma sintering Methods 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
239000012496 blank sample Substances 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
150000001733 carboxylic acid esters Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical group O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012809 cooling fluid Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
VTJCSBJRQLZNHE-CSMHCCOUSA-N desosamine Chemical group C[C@@H](O)C[C@H](N(C)C)[C@@H](O)C=O VTJCSBJRQLZNHE-CSMHCCOUSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000007599 discharging Methods 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012527 feed solution Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000004898 kneading Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
150000002646 long chain fatty acid esters Chemical class 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
229960000816 magnesium hydroxide Drugs 0.000 description 1
229960000869 magnesium oxide Drugs 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
235000019793 magnesium trisilicate Nutrition 0.000 description 1
229940099273 magnesium trisilicate Drugs 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229910000000 metal hydroxide Inorganic materials 0.000 description 1
150000004692 metal hydroxides Chemical class 0.000 description 1
229910044991 metal oxide Inorganic materials 0.000 description 1
150000004706 metal oxides Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
239000000693 micelle Substances 0.000 description 1
235000019691 monocalcium phosphate Nutrition 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229940044519 poloxamer 188 Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000007712 rapid solidification Methods 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
238000002098 selective ion monitoring Methods 0.000 description 1
238000004467 single crystal X-ray diffraction Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000010409 thin film Substances 0.000 description 1
230000007704 transition Effects 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Glanulating (AREA)

ZA200604495A 2003-12-04 2006-06-01 Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride ZA200604495B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US52724403P	2003-12-04	2003-12-04

Publications (1)

Publication Number	Publication Date
ZA200604495B true ZA200604495B (en)	2008-03-26

Family

ID=34652484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200604495A ZA200604495B (en)	2003-12-04	2006-06-01	Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride

Country Status (15)

Country	Link
US (1)	US20050158391A1 (zh)
EP (1)	EP1701702A1 (zh)
JP (1)	JP2007513143A (zh)
KR (2)	KR20080064209A (zh)
CN (1)	CN1889931A (zh)
AR (1)	AR046468A1 (zh)
AU (1)	AU2004294813A1 (zh)
BR (1)	BRPI0416535A (zh)
CA (1)	CA2547773A1 (zh)
IL (1)	IL175745A0 (zh)
NO (1)	NO20062389L (zh)
RU (1)	RU2006119464A (zh)
TW (1)	TW200528138A (zh)
WO (1)	WO2005053653A1 (zh)
ZA (1)	ZA200604495B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011039686A1 (en)	2009-09-30	2011-04-07	Pfizer Inc.	Latrepirdine oral sustained release dosage forms
CA2859174C (en) *	2011-12-12	2019-03-05	Orbis Biosciences, Inc.	Sustained release particle formulations
WO2013088274A1 (en)	2011-12-14	2013-06-20	Wockhardt Limited	Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
WO2019072877A1 (en) *	2017-10-10	2019-04-18	Capsugel Belgium Nv	GETTING MULTIPARTICULAR COMPOSITIONS
CN109288798A (zh) *	2018-12-08	2019-02-01	海南医学院	一种阿奇霉素掩味微球的制备方法
WO2021014360A1 (en)	2019-07-23	2021-01-28	Pfizer Inc.	Oral modified release dosage forms
WO2021094953A1 (en)	2019-11-14	2021-05-20	Pfizer Inc.	1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
WO2021231847A1 (en) *	2020-05-15	2021-11-18	Massachusetts Institute Of Technology	Oleogel and oleopaste compositions and uses thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6650A (en) *		1849-08-14		Edmund blunt
US3590A (en) *		1844-05-17		Rule or measure
US2955956A (en) *	1957-05-15	1960-10-11	Morton Salt Co	Process and apparatus for coating granules
US4092089A (en) *	1974-04-06	1978-05-30	Bayer Aktiengesellschaft	Apparatus for the preparation of melt-sprayed spherical phenacetin granules
US4086346A (en) *	1974-04-06	1978-04-25	Bayer Aktiengesellschaft	Preparation of melt-sprayed spherical phenacetin granules
US4053264A (en) *	1976-01-30	1977-10-11	United Technologies Corporation	Apparatus for making metal powder
US4293570A (en) *	1979-04-02	1981-10-06	Chimicasa Gmbh	Process for the preparation of sweetener containing product
YU43006B (en) *	1981-03-06	1989-02-28	Pliva Pharm & Chem Works	Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) *	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4675140A (en) *	1984-05-18	1987-06-23	Washington University Technology Associates	Method for coating particles or liquid droplets
US4874611A (en) *	1985-06-20	1989-10-17	The Dow Chemical Company	Microencapsulated ant bait
US5019302A (en) *	1986-03-12	1991-05-28	Washington University Technology Associates, Inc.	Method for granulation
US5100592A (en) *	1986-03-12	1992-03-31	Washington University Technology Associated, Inc.	Method and apparatus for granulation and granulated product
US5236734A (en) *	1987-04-20	1993-08-17	Fuisz Technologies Ltd.	Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5387431A (en) *	1991-10-25	1995-02-07	Fuisz Technologies Ltd.	Saccharide-based matrix
US5456932A (en) *	1987-04-20	1995-10-10	Fuisz Technologies Ltd.	Method of converting a feedstock to a shearform product and product thereof
WO1989000576A1 (en) *	1987-07-09	1989-01-26	Pfizer Inc.	Azithromycin dihydrate
WO1989002271A1 (en) *	1987-09-10	1989-03-23	Pfizer	Azithromycin and derivatives as antiprotozoal agents
DE3812567A1 (de) *	1988-04-15	1989-10-26	Basf Ag	Verfahren zur herstellung pharmazeutischer mischungen
US5064650A (en) *	1988-04-19	1991-11-12	Southwest Research Institute	Controlled-release salt sensitive capsule for oral use and adhesive system
US4931285A (en) *	1988-04-28	1990-06-05	Alza Corporation	Aqueous based pharmaceutical coating composition for dosage forms
US5024842A (en) *	1988-04-28	1991-06-18	Alza Corporation	Annealed coats
US5160743A (en) *	1988-04-28	1992-11-03	Alza Corporation	Annealed composition for pharmaceutically acceptable drug
US5047244A (en) *	1988-06-03	1991-09-10	Watson Laboratories, Inc.	Mucoadhesive carrier for delivery of therapeutical agent
US5084287A (en) *	1990-03-15	1992-01-28	Warner-Lambert Company	Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5213810A (en) *	1990-03-30	1993-05-25	American Cyanamid Company	Stable compositions for parenteral administration and method of making same
DE69111287T2 (de) *	1990-04-18	1995-12-21	Asahi Chemical Ind	Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.
US5183690A (en) *	1990-06-25	1993-02-02	The United States Of America, As Represented By The Secretary Of Agriculture	Starch encapsulation of biologically active agents by a continuous process
GB9014646D0 (en) *	1990-07-02	1990-08-22	Courtaulds Coatings Holdings	Coating compositions
US5194262A (en) *	1990-10-22	1993-03-16	Revlon Consumer Products Corporation	Encapsulated antiperspirant salts and deodorant/antiperspirants
US5196199A (en) *	1990-12-14	1993-03-23	Fuisz Technologies Ltd.	Hydrophilic form of perfluoro compounds and method of manufacture
US5292657A (en) *	1990-12-31	1994-03-08	Pioneer Hi-Bred International, Inc.	Process for preparing rotary disc fatty acid microspheres of microorganisms
US5143662A (en) *	1991-02-12	1992-09-01	United States Surgical Corporation	Process for preparing particles of bioabsorbable polymer
US5405617A (en) *	1991-11-07	1995-04-11	Mcneil-Ppc, Inc.	Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
GB9201857D0 (en) *	1992-01-29	1992-03-18	Smithkline Beecham Plc	Novel compound
JP3265680B2 (ja) *	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
DE4214272A1 (de) *	1992-05-04	1993-11-11	Nukem Gmbh	Verfahren und Vorrichtung zur Herstellung von Mikrokugeln
CA2095776C (en) *	1992-05-12	2007-07-10	Richard C. Fuisz	Rapidly dispersable compositions containing polydextrose
US5792474A (en) *	1992-05-22	1998-08-11	Goedecke Aktiengesellschaft	Process for the production of retarded pharmaceutical compositions
US5518730A (en) *	1992-06-03	1996-05-21	Fuisz Technologies Ltd.	Biodegradable controlled release flash flow melt-spun delivery system
TW271400B (zh) *	1992-07-30	1996-03-01	Pfizer
US5348758A (en) *	1992-10-20	1994-09-20	Fuisz Technologies Ltd.	Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) *	1992-10-23	1995-01-10	Fuisz Technologies Ltd.	Process for making shearform matrix
GB9224855D0 (en) *	1992-11-27	1993-01-13	Smithkline Beecham Plc	Pharmaceutical compositions
US5569467A (en) *	1993-05-15	1996-10-29	Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.)	Process for the preparation of microballs and microballs thus obtained
IL109770A0 (en) *	1993-05-29	1994-11-28	Smithkline Beecham Corp	Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5597416A (en) *	1993-10-07	1997-01-28	Fuisz Technologies Ltd.	Method of making crystalline sugar and products resulting therefrom
US5935600A (en) *	1993-09-10	1999-08-10	Fuisz Technologies Ltd.	Process for forming chewable quickly dispersing comestible unit and product therefrom
US5433951A (en) *	1993-10-13	1995-07-18	Bristol-Myers Squibb Company	Sustained release formulation containing captopril and method
AT401871B (de) *	1994-01-28	1996-12-27	Gebro Broschek Gmbh	Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
WO1995025504A1 (en) *	1994-03-18	1995-09-28	Pharmavene, Inc.	Emulsified drug delivery systems
US5605889A (en) *	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
PT758244E (pt) *	1994-05-06	2002-04-29	Pfizer	Formas de dosagem libertacao controlada de azitromicina
DE19509807A1 (de) *	1995-03-21	1996-09-26	Basf Ag	Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5567439A (en) *	1994-06-14	1996-10-22	Fuisz Technologies Ltd.	Delivery of controlled-release systems(s)
US5582855A (en) *	1994-07-01	1996-12-10	Fuisz Technologies Ltd.	Flash flow formed solloid delivery systems
US5556652A (en) *	1994-08-05	1996-09-17	Fuisz Technologies Ltd.	Comestibles containing stabilized highly odorous flavor component delivery systems
US5601761A (en) *	1994-09-26	1997-02-11	The Dow Chemical Company	Encapsulated active materials and method for preparing same
US5683720A (en) *	1994-10-28	1997-11-04	Fuisz Technologies Ltd.	Liquiflash particles and method of making same
US5965164A (en) *	1994-10-28	1999-10-12	Fuisz Technologies Ltd.	Recipient-dosage delivery system
US5965161A (en) *	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
FR2732621B1 (fr) *	1995-04-10	1997-06-06	Rhone Poulenc Chimie	Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention
EP0826376B1 (en) *	1995-05-02	2007-01-24	Taisho Pharmaceutical Co. Ltd	Composition for oral administration
US5747058A (en) *	1995-06-07	1998-05-05	Southern Biosystems, Inc.	High viscosity liquid controlled delivery system
US5883103A (en) *	1995-06-07	1999-03-16	Shire Laboratories Inc.	Oral acyclovir delivery
US5855915A (en) *	1995-06-30	1999-01-05	Baylor University	Tablets or biologically acceptable implants for long-term antiinflammatory drug release
EP0784933A3 (en) *	1995-10-16	1997-11-26	Leaf, Inc.	Extended release of additives in comestible products
US5919489A (en) *	1995-11-01	1999-07-06	Abbott Laboratories	Process for aqueous granulation of clarithromycin
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
DE19629753A1 (de) *	1996-07-23	1998-01-29	Basf Ag	Verfahren zur Herstellung von festen Arzneiformen
US6139872A (en) *	1996-08-14	2000-10-31	Henkel Corporation	Method of producing a vitamin product
HRP970485A2 (en) *	1996-09-13	1998-08-31	Joerg Rosenberg	Process for producing solid pharmaceutical forms
US5948407A (en) *	1997-03-19	1999-09-07	Shire Laboratories Inc.	Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6010718A (en) *	1997-04-11	2000-01-04	Abbott Laboratories	Extended release formulations of erythromycin derivatives
US6551616B1 (en) *	1997-04-11	2003-04-22	Abbott Laboratories	Extended release formulations of erythromycin derivatives
DE19729487A1 (de) *	1997-07-10	1999-01-14	Dresden Arzneimittel	Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
SI9700186B (sl) *	1997-07-14	2006-10-31	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D.	Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US5869098A (en) *	1997-08-20	1999-02-09	Fuisz Technologies Ltd.	Fast-dissolving comestible units formed under high-speed/high-pressure conditions
DE69828635T2 (de) *	1997-09-19	2005-06-16	Shire Laboratories, Inc.	Feste lösungskügelchen
IE970731A1 (en) *	1997-10-07	2000-10-04	Fuisz Internat Ltd	Product and method for the treatment of hyperlipidemia
US6013280A (en) *	1997-10-07	2000-01-11	Fuisz Technologies Ltd.	Immediate release dosage forms containing microspheres
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US5891845A (en) *	1997-11-21	1999-04-06	Fuisz Technologies Ltd.	Drug delivery systems utilizing liquid crystal structures
EP1037607B1 (en) *	1997-12-08	2004-02-25	ALTANA Pharma AG	Novel suppository form comprising an acid-labile active compound
US6270804B1 (en) *	1998-04-03	2001-08-07	Biovail Technologies Ltd.	Sachet formulations
US6117452A (en) *	1998-08-12	2000-09-12	Fuisz Technologies Ltd.	Fatty ester combinations
US6086920A (en) *	1998-08-12	2000-07-11	Fuisz Technologies Ltd.	Disintegratable microspheres
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en) *	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1246831B1 (en) *	2000-01-04	2008-03-05	Teva Pharmaceutical Industries Ltd.	Preparation method of azithromycin dihydrate
IT1320176B1 (it) *	2000-12-22	2003-11-26	Nicox Sa	Dispersioni solide di principi attivi nitrati.
PT1368006E (pt) *	2001-02-13	2006-08-31	Astrazeneca Ab	Nova formulacao de libertacao modificada
ES2305434T3 (es) *	2002-02-01	2008-11-01	Pfizer Products Inc.	Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US6682759B2 (en) *	2002-02-01	2004-01-27	Depomed, Inc.	Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AR038375A1 (es) *	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo

2004
- 2004-11-22 CN CNA2004800358177A patent/CN1889931A/zh active Pending
- 2004-11-22 KR KR1020087015425A patent/KR20080064209A/ko not_active Application Discontinuation
- 2004-11-22 KR KR1020067011027A patent/KR20060109481A/ko not_active Application Discontinuation
- 2004-11-22 BR BRPI0416535-7A patent/BRPI0416535A/pt not_active IP Right Cessation
- 2004-11-22 WO PCT/IB2004/003839 patent/WO2005053653A1/en active Application Filing
- 2004-11-22 EP EP04798952A patent/EP1701702A1/en not_active Withdrawn
- 2004-11-22 CA CA002547773A patent/CA2547773A1/en not_active Abandoned
- 2004-11-22 AU AU2004294813A patent/AU2004294813A1/en not_active Abandoned
- 2004-11-22 RU RU2006119464/15A patent/RU2006119464A/ru unknown
- 2004-11-22 JP JP2006542040A patent/JP2007513143A/ja not_active Abandoned
- 2004-12-01 TW TW093137051A patent/TW200528138A/zh unknown
- 2004-12-03 US US11/003,856 patent/US20050158391A1/en not_active Abandoned
- 2004-12-03 AR ARP040104514A patent/AR046468A1/es unknown
2006
- 2006-05-18 IL IL175745A patent/IL175745A0/en unknown
- 2006-05-24 NO NO20062389A patent/NO20062389L/no not_active Application Discontinuation
- 2006-06-01 ZA ZA200604495A patent/ZA200604495B/en unknown

Also Published As

Publication number	Publication date
US20050158391A1 (en)	2005-07-21
RU2006119464A (ru)	2007-12-20
NO20062389L (no)	2006-06-16
WO2005053653A1 (en)	2005-06-16
BRPI0416535A (pt)	2007-01-09
AU2004294813A1 (en)	2005-06-16
AR046468A1 (es)	2005-12-07
IL175745A0 (en)	2006-09-05
EP1701702A1 (en)	2006-09-20
CN1889931A (zh)	2007-01-03
TW200528138A (en)	2005-09-01
JP2007513143A (ja)	2007-05-24
KR20080064209A (ko)	2008-07-08
KR20060109481A (ko)	2006-10-20
CA2547773A1 (en)	2005-06-16

Publication	Publication Date	Title
EP1537859B1 (en)	2008-09-10	Azithromycin dosage forms with reduced side effects
ZA200604495B (en)	2008-03-26	Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US20050181061A1 (en)	2005-08-18	Extrusion process for forming chemically stable drug multiparticulates
EP1691787B1 (en)	2008-07-02	Method for making pharmaceutical multiparticulates
AU2004216676B2 (en)	2011-06-16	Azithromycin dosage forms with reduced side effects
US20050152982A1 (en)	2005-07-14	Controlled release multiparticulates formed with dissolution enhancers
US20050123615A1 (en)	2005-06-09	Controlled release dosage forms of azithromycin
MXPA06006265A (en)	2006-10-17	Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
AU2004294818A1 (en)	2005-06-16	Azithromycin multiparticulate dosage forms by liquid-based processes
MXPA06006264A (en)	2006-10-17	Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride